Analysis of humoral and cellular responses after vaccination against SARS-CoV-2 in patients with immune-mediated diseases DOI
Thomas Escoda,

Sylvie Jordana,

L. Chiche

et al.

Diagnostic Microbiology and Infectious Disease, Journal Year: 2025, Volume and Issue: 112(3), P. 116825 - 116825

Published: April 6, 2025

Language: Английский

The biological and clinical significance of emerging SARS-CoV-2 variants DOI Creative Commons
Kaiming Tao, Philip L. Tzou, Janin Nouhin

et al.

Nature Reviews Genetics, Journal Year: 2021, Volume and Issue: 22(12), P. 757 - 773

Published: Sept. 17, 2021

Language: Английский

Citations

991
SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19 DOI Creative Commons
Alba Grifoni, John Sidney, Randi Vita

et al.

Cell Host & Microbe, Journal Year: 2021, Volume and Issue: 29(7), P. 1076 - 1092

Published: May 21, 2021

Language: Английский

Citations

298
T Cell Memory: Understanding COVID-19 DOI Creative Commons
Nicholas N. Jarjour, David Masopust, Stephen C. Jameson

et al.

Immunity, Journal Year: 2020, Volume and Issue: 54(1), P. 14 - 18

Published: Dec. 19, 2020

Language: Английский

Citations

154
How to interpret and use COVID-19 serology and immunology tests DOI Creative Commons
David S. Y. Ong, Paraskevi C. Fragkou, Valentijn A. Schweitzer

et al.

Clinical Microbiology and Infection, Journal Year: 2021, Volume and Issue: 27(7), P. 981 - 986

Published: May 9, 2021

Language: Английский

Citations

128
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial DOI Open Access
Jingxin Li, Shipo Wu,

Xiling Guo

et al.

The Lancet Respiratory Medicine, Journal Year: 2022, Volume and Issue: 10(8), P. 739 - 748

Published: May 20, 2022

Language: Английский

Citations

124
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge DOI Creative Commons
Anthony DiPiazza, Sarah R. Leist, Olubukola M. Abiona

et al.

Immunity, Journal Year: 2021, Volume and Issue: 54(8), P. 1869 - 1882.e6

Published: July 2, 2021

Language: Английский

Citations

89
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need DOI Creative Commons
Pengfei Jin, Jingxin Li, Hongxing Pan

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2021, Volume and Issue: 6(1)

Published: Feb. 2, 2021

Abstract In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help avoid large-scale filed efficacy trials facilitate approval candidates, which is crucial control COVID-19 pandemic. Several phase 3 way, provide opportunities for determination correlates protection. this paper, we review current knowledge existence protection, methods assessment immune protection issues related

Language: Английский

Citations

88
Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β DOI Creative Commons
Chiara Colarusso, Angelantonio Maglio,

Michela Terlizzi

et al.

Biomedicines, Journal Year: 2021, Volume and Issue: 9(12), P. 1931 - 1931

Published: Dec. 17, 2021

SARS-CoV-2 infection induces in some patients a condition called long-COVID-19, herein post-COVID-19 (PC), which persists for longer than the negative oral-pharyngeal swab. One of complications PC is pulmonary fibrosis. The purpose this study was to identify blood biomarkers predict undergoing fibrosis.We analyzed samples healthy, anti-SARS-CoV-2 vaccinated (VAX) subjects and who were stratified according severity disease chest computed tomography (CT) scan data.The inflammatory C reactive protein (CRP), complement complex C5b-9, LDH, but not IL-6, higher patients, independent lung fibrotic areas. Interestingly, with ground-glass opacities (as revealed by CT scan) characterized plasma levels IL-1α, CXCL-10, TGF-β, IFN-β, compared healthy VAX subjects. In particular, 19 out 23 (82.6%) severe 8 29 (27.6%) moderate presented signs fibrosis, associated lower IL-1α TGF-β.We found that TGF-β IFN-β could an increased relative risk (RR = 2.8) fibrosis-like changes patients.

Language: Английский

Citations

61
The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity DOI Creative Commons
Wenjing Gu, Hui Gan, Yu Ma

et al.

Virology Journal, Journal Year: 2022, Volume and Issue: 19(1)

Published: March 19, 2022

The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has resulted in a global health emergency (COVID-19) because of its rapid spread and high mortality. Since the virus epidemic, many pathogenic mechanisms have been revealed, virus-related vaccines successfully developed applied clinical practice. However, pandemic is still developing, new mutations are emerging. Virus pathogenicity closely related to immune status host. As innate immunity body's first defense against viruses, understanding inhibitory effect SARS-CoV-2 on great significance for determining target antiviral intervention. This review summarizes molecular mechanism by which escapes host system, including suppressing production blocking adaptive priming. Here, one hand, we devoted ourselves summarizing combined action cells, cytokines, chemokines fine-tune outcome infection immunopathogenesis. On other focused effects immunity, enhancing viral adhesion, increasing rate invasion, inhibiting transcription translation immune-related mRNA, cellular mRNA degradation, protein transmembrane transport. underlying should provide theoretical support developing future targeted drugs SARS-CoV-2. Nevertheless, completely virus, people's it process growth, various studies also being carried out. Although strive make our as inclusive possible, there may be incompleteness.

Language: Английский

Citations

55
Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients DOI Creative Commons
Matthijs Oyaert, Marie‐Angélique De Scheerder,

Sophie Van Herrewege

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: March 22, 2022

Immunocompromised patients are at increased risk of severe COVID-19 and impaired vaccine response. In this observational prospective study, we evaluated immunogenicity the BNT162b2 mRNA in cohorts primary or secondary immunocompromised patients.Five clinical groups [primary immunodeficiency (PID) (n=57), people living with HIV (PLWH) (n=27), a broad variety underlying rheumatologic (n=23) homogeneous (multiple sclerosis) neurologic (n=53) conditions chronic kidney disease (CKD) (n=39)] as well healthy control group (n=54) were included. Systemic humoral cellular immune responses by determination anti-SARS-CoV-2 Spike antibodies using TrimericS IgG assay (Diasorin) through quantification interferon gamma release response to SARS-CoV-2 antigen QuantiFERON (Qiagen), respectively. Responses measured pre-defined time-points after complete vaccination.All controls, PLWH CKD-patients had detectable 10 14 days (T2) 3 months (T3) administration second vaccination. contrast, only 94.5% PID, 50.0% 48.0% developed T2 89.1% 52.4% T3. At T3 no significant differences between CKD found, while proportions reactive subjects lower PID higher patients. Humoral significantly correlated control, for all antigens.Patients acquired inherited disorders may show variable vaccination against SARS-CoV-2. Whether humoral, both delayed depends on patient group, therapy individual factors. These data guide counselling regarding

Language: Английский

Citations

54